Delving into ABBV-383, a Novel Bispecific Antibody with Enhanced Tumor Targeting & Optimized T-cell Engagement in Multiple Myeloma
Time: 9:30 am
day: Day One
Details:
- Scientific rationale for high avidity tumor antigen binding coupled with low affinity CD3 T-cell engagement by ABBV-383
- Translation of unique design attributes of ABBV-383 to the clinic
- Clinical updates on ABBV-383 in patient with relapsed or refractory multiple myeloma
